The role of angiotensin-converting enzyme 2 in COVID-19 induced lung injury

Main Article Content

Sara Torabi
Farbod Bahreini
Nima Rezaei

Keywords

Angiotensin-converting enzyme 2, COVID-19, Lung injury

Abstract

The novel coronavirus disease (COVID-19) has affected people around the world both physically and psychologically. As result, developing coronavirus-specific vaccine and/or therapeutics is now a top priority for public health agencies. Since our findings about COVID-19 are relatively new, the current knowledge about the molecular mechanism involved in pathogenicity and virulence of the novel coronavirus is not advanced. Understanding angiotensin-converting enzyme 2 (ACE2), the receptor for the coronavirus, is significantly important. To better illustrate the role of ACE2 in the severity of COVID-19 and the impact of currently used drugs on this receptor, this paper briefly reviews newly published articles in this regard.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...
Abstract 9 |

References

1. CHENG H, WANG Y, WANG GQ. Organ‐protective effect of angiotensin‐converting enzyme 2 and its effect on the prognosis of COVID‐19. J Med Virol 2020
2. CHENG P, ZHU H, WITTELES RM, et al., Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty. Curr Cardiol Rep 2020; 22(5): 34
3. DEVAUX CA, ROLAIN J-M, COLSON P, RAOULT D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020: 105938
4. GOLSHANI M, SAGHAZADEH A, REZAEI N. SARS-CoV-2–a tough opponent for the immune system. Arch Med Res 2020
5. GUPTA R, MISRA A. Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc). Diabetes Metab Syndr 2020
6. HOFFMANN M, SCHROEDER S, KLEINE-WEBER H, MÜLLER MA, DROSTEN C, PÖHLMANN S. Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19. Antimicrob Agents Chemother 2020
7. KAI H, KAI M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors—lessons from available evidence and insights into COVID-19. Hypertens Res 2020: 1-7
8. LEUNG JM, YANG CX, TAM A, et al., ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J 2020; 55(5)
9. LI Y, ZENG Z, CAO Y, et al., Angiotensin-converting enzyme 2 prevents lipopolysaccharide-induced rat acute lung injury via suppressing the ERK1/2 and NF-κB signaling pathways. Sci Rep 2016; 6: 27911
10. LIU Y, YAN L-M, WAN L, et al., Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis 2020
11. LOTFI M, HAMBLIN MR, REZAEI N. COVID-19: transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta 2020; 508: 254-66
12. MOMTAZMANESH S, OCHS HD, UDDIN LQ, et al., All together to Fight Novel Coronavirus Disease (COVID-19) Am J Trop Med Hyg 2020
13. SAGHAZADEH A, REZAEI N. Immune-epidemiological parameters of the novel coronavirus – a perspective. Expert Rev Clin Immunol 2020
14. SAGHAZADEH A, REZAEI N. Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids. Int Immunopharmacol 2020; 84(106560): 1-6
15. SKALNY AV, RINK L, AJSUVAKOVA OP, et al., Zinc and respiratory tract infections: Perspectives for COVID‑19. Int J Mol Med 2020; 46(1): 17-26
16. YAZDANPANAH F, HAMBLIN MR, REZAEI N. The immune system and COVID-19: friend or foe? Life Sci 2020
17. ZHENG Z, PENG F, XU B, et al., Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infection 2020